MSN Labs enters into licence agreement with DRDO for 2-DG
Developed by the DRDO, 2-DG has been granted permission by Drug Controller General of India for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
Hyderabad: Hyderabad-based MSN Laboratories entered into a licence agreement with Defence Research & Development Establishment, Institute of Nuclear Medicine and Allied Sciences establishments of Defence Research & Development Organisation for the manufacturing, distribution and marketing of 2- Deoxy-D-Glucose (2-DG) in India.
Developed by the DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
MSN Labs will be launching the 2 DG as a twice a day product in sachet form under the brand name MSN 2D in strength of 2.34 g.
As part of the Covid treatment range, MSN has already launched other anti-viral medications like Oseltamivir capsules under the brand name ‘’Oselow’’; anti Covid medications such as Favipiravir under the brand name ‘’Favilow”; Baricitinib under the brand name ‘’Baridoz” and antifungal medication such as Posaconazole under the brand name ‘’Posaone”.
MSN is conducting clinical trials with investigational drugs such as Aviptadil on severe hospitalised patients and with Molnupiravir on mild and moderate Covid patients.
MSN has nine bulk drugs and five finished dosage facilities in Hyderabad and the US. The group has an integrated R&D centre for both bulk drugs and formulation under one roof, dedicated to research and development of pharmaceuticals. The company has 650 national and international patents, and a product portfolio of over 410 bulk drugs and 250 formulations covering more than 35 major therapies.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
